FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155459097> ?p ?o ?g. }

• W2155459097 endingPage "3528" @default.
• W2155459097 startingPage "3520" @default.
• W2155459097 abstract "Abstract Recent investigations have documented that constitutively activated phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling is a common feature of T-cell acute lymphoblastic leukemia (T-ALL), where it strongly influences growth and survival. These findings lend compelling weight for the application of PI3K/Akt/mTOR inhibitors in T-ALL. However, our knowledge of PI3K/Akt/mTOR signaling in T-ALL is limited and it is not clear whether it could be an effective target for innovative therapeutic strategies. Here, we have analyzed the therapeutic potential of the dual PI3K/mTOR inhibitor PI-103, a small synthetic molecule of the pyridofuropyrimidine class, on both T-ALL cell lines and patient samples, which displayed constitutive activation of PI3K/Akt/mTOR signaling. PI-103 inhibited the growth of T-ALL cells, including 170-kDa P-glycoprotein overexpressing cells. PI-103 cytotoxicity was independent of p53 gene status. PI-103 was more potent than inhibitors that are selective only for PI3K (Wortmannin, LY294002) or for mTOR (rapamycin). PI-103 induced G0-G1 phase cell cycle arrest and apoptosis, which was characterized by activation of caspase-3 and caspase-9. PI-103 caused Akt dephosphorylation, accompanied by dephosphorylation of the Akt downstream target, glycogen synthase kinase-3β. Also, mTOR downstream targets were dephosphorylated in response to PI-103, including p70S6 kinase, ribosomal S6 protein, and 4E-BP1. PI-103 strongly synergized with vincristine. These findings indicate that multitargeted therapy toward PI3K and mTOR alone or with existing drugs may serve as an efficient treatment toward T-ALL cells, which require up-regulation of PI3K/Akt/mTOR signaling for their survival and growth. [Cancer Res 2009;69(8):3520–28]" @default.
• W2155459097 created "2016-06-24" @default.
• W2155459097 creator A5016580949 @default.
• W2155459097 creator A5018652598 @default.
• W2155459097 creator A5030391285 @default.
• W2155459097 creator A5032095675 @default.
• W2155459097 creator A5037164805 @default.
• W2155459097 creator A5053869150 @default.
• W2155459097 creator A5058584326 @default.
• W2155459097 creator A5071715614 @default.
• W2155459097 creator A5090502867 @default.
• W2155459097 date "2009-04-15" @default.
• W2155459097 modified "2023-09-25" @default.
• W2155459097 title "Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia" @default.
• W2155459097 cites W1599602125 @default.
• W2155459097 cites W1969222622 @default.
• W2155459097 cites W1972477446 @default.
• W2155459097 cites W1974055303 @default.
• W2155459097 cites W1983698019 @default.
• W2155459097 cites W1987759199 @default.
• W2155459097 cites W1988184140 @default.
• W2155459097 cites W1988976358 @default.
• W2155459097 cites W1992925022 @default.
• W2155459097 cites W1997353102 @default.
• W2155459097 cites W2027241628 @default.
• W2155459097 cites W2030711372 @default.
• W2155459097 cites W2030899725 @default.
• W2155459097 cites W2039830346 @default.
• W2155459097 cites W2041175983 @default.
• W2155459097 cites W2043804636 @default.
• W2155459097 cites W2048206336 @default.
• W2155459097 cites W2053861460 @default.
• W2155459097 cites W2054299798 @default.
• W2155459097 cites W2056638182 @default.
• W2155459097 cites W2061484053 @default.
• W2155459097 cites W2074433596 @default.
• W2155459097 cites W2075291089 @default.
• W2155459097 cites W2078948501 @default.
• W2155459097 cites W2087012714 @default.
• W2155459097 cites W2094709780 @default.
• W2155459097 cites W2098189424 @default.
• W2155459097 cites W2105435030 @default.
• W2155459097 cites W2106933841 @default.
• W2155459097 cites W2109467838 @default.
• W2155459097 cites W2115484306 @default.
• W2155459097 cites W2128750703 @default.
• W2155459097 cites W2140154966 @default.
• W2155459097 cites W2149320251 @default.
• W2155459097 cites W2150186278 @default.
• W2155459097 cites W2151686058 @default.
• W2155459097 cites W2154964377 @default.
• W2155459097 cites W2157033268 @default.
• W2155459097 cites W2157882510 @default.
• W2155459097 cites W2158305336 @default.
• W2155459097 cites W2159299361 @default.
• W2155459097 cites W2159530979 @default.
• W2155459097 cites W2166295047 @default.
• W2155459097 cites W2168443282 @default.
• W2155459097 cites W2172162633 @default.
• W2155459097 cites W2405657090 @default.
• W2155459097 cites W2564125894 @default.
• W2155459097 doi "https://doi.org/10.1158/0008-5472.can-08-4884" @default.
• W2155459097 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3836286" @default.
• W2155459097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19351820" @default.
• W2155459097 hasPublicationYear "2009" @default.
• W2155459097 type Work @default.
• W2155459097 sameAs 2155459097 @default.
• W2155459097 citedByCount "115" @default.
• W2155459097 countsByYear W21554590972012 @default.
• W2155459097 countsByYear W21554590972013 @default.
• W2155459097 countsByYear W21554590972014 @default.
• W2155459097 countsByYear W21554590972015 @default.
• W2155459097 countsByYear W21554590972016 @default.
• W2155459097 countsByYear W21554590972017 @default.
• W2155459097 countsByYear W21554590972018 @default.
• W2155459097 countsByYear W21554590972019 @default.
• W2155459097 countsByYear W21554590972020 @default.
• W2155459097 countsByYear W21554590972021 @default.
• W2155459097 countsByYear W21554590972022 @default.
• W2155459097 countsByYear W21554590972023 @default.
• W2155459097 crossrefType "journal-article" @default.
• W2155459097 hasAuthorship W2155459097A5016580949 @default.
• W2155459097 hasAuthorship W2155459097A5018652598 @default.
• W2155459097 hasAuthorship W2155459097A5030391285 @default.
• W2155459097 hasAuthorship W2155459097A5032095675 @default.
• W2155459097 hasAuthorship W2155459097A5037164805 @default.
• W2155459097 hasAuthorship W2155459097A5053869150 @default.
• W2155459097 hasAuthorship W2155459097A5058584326 @default.
• W2155459097 hasAuthorship W2155459097A5071715614 @default.
• W2155459097 hasAuthorship W2155459097A5090502867 @default.
• W2155459097 hasBestOaLocation W21554590971 @default.
• W2155459097 hasConcept C11960822 @default.
• W2155459097 hasConcept C184235292 @default.
• W2155459097 hasConcept C185592680 @default.
• W2155459097 hasConcept C2776912716 @default.
• W2155459097 hasConcept C2778308172 @default.
• W2155459097 hasConcept C2780610907 @default.
• W2155459097 hasConcept C43060935 @default.

• next